InvestorsHub Logo
Followers 44
Posts 4776
Boards Moderated 0
Alias Born 06/20/2007

Re: None

Thursday, 03/26/2015 7:39:19 AM

Thursday, March 26, 2015 7:39:19 AM

Post# of 50662
I think with this type of deal MultiCell landed the bigger players in pharma (Novartis, etc) must be getting wind of what's going on here. On this deal alone MultiCell can buy back all the shares at this price if they wanted to. Major potential here.

In event of completion of all clinical development, OXIS will make an additional payment of $22.75 million to MCIT. It will also pay a royalty of 3% of net annual worldwide sales.